Preferred Label : Siponimod Fumarate;
NCIt synonyms : 3-Azetidinecarboxylic Acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-,
(2E)-2-Butenedioate (2:1;
NCIt related terms : SIPONIMOD FUMARIC ACID;
NCIt definition : The fumarate salt form of siponimod, an orally bioavailable sphingosine 1-phosphate
(S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities.
Upon oral administration, siponimod targets and binds to S1P receptors 1 and 5 on
lymphocytes. This prevents the egress of lymphocytes from lymph nodes, thereby reducing
both the number of circulating peripheral lymphocytes and the infiltration of lymphocytes
into target tissues, such as the central nervous system (CNS). This prevents lymphocyte-mediated
immune response and may reduce inflammation. S1P plays a key role in lymphocyte migration
from lymphoid tissues. Siponimod does not target S1P receptor 3, the activation of
which may be responsible for adverse effects such as bradycardia associated with other
S1P receptor modulators.;
UNII : Z7G02XZ0M6;
InChIKey : JNLIKIBISICTMS-PEJBKAKVSA-N;
CAS number : 1234627-85-0;
Drug name : Mayzent;
NCI Metathesaurus CUI : CL1382617;
Origin ID : C170378;
UMLS CUI : C4764663;
Semantic type(s)
- concept_is_in_subset
